LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the receipt of two US new patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,709,224, covers methods for manufacturing recombinant antibodies. By incorporating our 2A/Furin technology into antibody-expression in viral vectors it is possible to rapidly generate stable, high producing antibody cell lines. The subsequent cell lines may greatly reduce the time and lower the cost of commercial antibody production. The second issued US patent, US Pat. No. 7,714,199 covers additional adeno-associated virus (AAV) vectors containing the 2A/furin technology and methods for expressing antibodies in vivo using these vectors and builds on already issued patents covering vectors and methods for producing antibodies in vivo and in vitro. The two new patents expire in 2023.
